Patel Snehal purchased $30K of GLSI

Patel Snehal (CEO and CFO) purchased 2,200 shares of Greenwich LifeSciences, Inc. (GLSI) at an average of $13.43 ($13.10–$13.59) across 2 trades over 2026-07-28 to 2026-07-29.

Original reporting
SEC EDGAR · Patel Snehal
Published Jul 30, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 10:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GLSI
Bullish
medium confidence
Mentioned
$GLSI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLSIBullishLow
01

Why it matters

Insider buying can be interpreted as confidence, but the disclosed amount is modest and lacks additional fundamental details in the filing text.

02

Market read

Traders may note the insider purchase as a small positive sentiment datapoint, but it is unlikely to be a standalone catalyst.

03

What to watch

The article does not provide context on prior insider activity, whether the purchase was discretionary, or any concurrent company-specific catalysts (earnings, trials, contracts).

Relevance 4/10Novelty 5/10Timing: filed 2026-07-30, covering purchases on 2026-07-28 to 2026-07-29

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Greenwich LifeSciences, Inc.

Company-level read

Ticker impact

$GLSIBullishMedium confidence
Context

SEC Form 4 shows CEO/CFO Patel Snehal bought 2,200 shares of Greenwich LifeSciences at $13.10 to $13.59 (about $29.6K).

Expected impact

Likely minimal immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction value (~$29.6K) is small relative to typical market-moving thresholds, and there is no 10b5-1 plan disclosed.

Market effects

No sector-level implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or pre-planned personal allocation rather than a bullish view on near-term performance.

Key entities

  • Greenwich LifeSciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Patel Snehal

    CEO and CFO, reported open-market purchase of GLSI shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GLSIMedAI 8/10

RedChip Companies, Inc.: Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

Greenwich LifeSciences (GLSI) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV and CNBC. CEO Snehal Patel discusses GLSI-100, an immunotherapy for HER2-positive breast cancer, highlighting an 80% reduction in recurrence in trials. The company is expanding its Phase III trial and exploring broader patient eligibility. GLSI aims to double its target population to 88,000 patients in the U.S. and Europe.

$GLSIMedAI 8/10

Greenwich LifeSciences presents at BIO-Europe 2026 in Cologne

Greenwich LifeSciences (GLSI) presented at BIO-Europe 2026, discussing its phase three trial (Flamingo-1) for early breast cancer. The trial, led by Baylor College of Medicine, has 180 sites in the US and Europe, with plans to expand. The company reported an 80% reduction in recurrence rate in phase two trials. GLSI is publicly traded, has raised $60M since IPO, and is fast track designated. Management owns 75-85% of the company, with a low float and extended lockup until January 2027.

$GLSIMedAI 8/10

Greenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes

Greenwich LifeSciences (GLSI) said U.S. and European regulators approved changes to its FLAMINGO-01 Phase III trial of GLSI-100 for breast cancer recurrence. The DSMB recommended continuing without changes. Enrollment now includes non-HLA-A*02 patients, expected to more than double enrollment rate. In a 250-patient arm, preliminary results show a 70-80% recurrence reduction. Cash was about $8.9M at June 30, 2026.